OptimizeRx Corporation (OPRX)
After hours:
| Previous close | 10.00 |
| Open | 10.00 |
| Bid | 9.94 x 200 |
| Ask | 10.02 x 100 |
| Day's range | 9.84 - 10.05 |
| 52-week range | 6.92 - 16.65 |
| Volume | |
| Avg. volume | 139,503 |
| Market cap | 182.15M |
| Beta (5Y monthly) | 1.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.04 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.33 |
Simply Wall St.OptimizeRx (NASDAQ:OPRX) shareholders have endured a 83% loss from investing in the stock three years ago
Every investor on earth makes bad calls sometimes. But you have a problem if you face massive losses more than once in...
GlobeNewswireNew White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations
• 84% of Patients Arrive at Doctor Visits Underinformed• Underscores Growing Importance of HCP and DTC Alignment in Pharma Commercialization and Marketing Strategies• OPRX Closes First Combined HCP and DTC DAAP Marketing Program for Top 5 Pharma Client WALTHAM, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients,
- GlobeNewswire
OptimizeRx Reports First Quarter 2024 Financial Results
Q1 revenue of $19.7 million, increasing 51% year-over-yearQ1 gross profit increased 64% year-over-year to $12.2 million with a gross margin of 62%Won 9 DAAP deals during Q1 WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended March 31, 2024. Quarterly comparis
